ArticleBMC ophthalmology2026
Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to evaluate the long-term outcome of a treat-and-extend regimen (TER) in treatment-naïve patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
methodsA retrospective analysis was conducted on a consecutive series of patients treated with either ranibizumab 0.5 mg or aflibercept 2 mg in a treat-and-extend regimen without a loading dose with follow-up of at least 12 months. The evaluation included best-corrected visual acuity (BCVA), central retinal thickness (CRT), other morphological parameters assessed by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA) as well as treatment frequency.
resultsn = 106 (mean age 72.2 ± 11.2 years) were included, 55 BRVO and 51 CRVO/Hemi-CRVO. Mean follow-up period 54.1 ± 30.7 months (range 12–142). 36 eyes discontinued treatment: 9 eyes due to success and 27 lost to follow-up/death and 2 switched to Faricimab. BCVA significantly increased from 57.4 ± 23.9 letters at baseline to 72.6 ± 13.8 (p < 0.001), 72.3 ± 15.2 (p < 0.001), 72.4 ± 15.6 (p < 0.001), and 73.3 ± 13.5 letters (p < 0.001) after 1, 2, 3 and 4 years respectively. CRT significantly decreased from 506 ± 195 μm at baseline to 281 ± 72 μm (p < 0.001), 282 ± 64 μm (p < 0.001), 279 ± 72 μm (p < 0.001), and 283 ± 89 μm (p < 0.001), after 1, 2, 3 and 4 years, respectively. At year 1, 46.2% of eyes showed a dry retina (no intra- or subretinal fluid); at year 2, 48.0%; at year 3, 54.4%; and at year 4, 44.0%. Mean number of injections was 9.8 ± 2.2, 8.2 ± 2.5, 7.5 ± 3.1, and 7.3 ± 2.2 at years 1, 2, 3, and 4, respectively. The mean maximal recurrence-free treatment interval was 6.4 ± 2.1, 8.1 ± 2.7, 8.7 ± 2.8, and 8.5 ± 2.6 weeks within years 1, 2, 3, and 4, respectively.
conclusionLong-term treat-and-extend regimen treatment using ranibizumab or aflibercept in treatment-naïve patients with CME due to BRVO or CRVO led to statistically significant and sustained functional and morphological improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.